Market news

WAYNE, Pa., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to six new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 78,000 shares of common stock (the “Options”) as

WAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: Cantor Global Healthcare Conference 2026 Fireside ChatSeptember 10, 2026, at 8:00 am ET Morgan Stanley 24th Annual Global Healthcare Conference 1x1 meetings onlySeptember 16, 20

Christopher Ryan Sullivan, Chief Financial Officer, on August 17, 2026, sold 72,725 shares in Avalo

Avalo Therapeutics, Inc. reported past earnings for the second quarter and first half of 2026, with net losses of US$36.36 million and US$55.99 million respectively, both higher than the same periods a year earlier. Despite the larger overall losses, the basic and diluted loss per share from continuing operations improved year-on-year for both the quarter and the six-month period, hinting at progress in managing shareholder dilution or capital structure. With this backdrop of higher net...

Detailed price information for Avalo Therapeutics Inc (AVTX-Q) from The Globe and Mail including charting and trades.

WAYNE, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that Dr. Garry Neil, Chief Executive Officer of Avalo, will participate in the “Honing in on Hidradenitis” panel at the virtual BTIG Biotechnology Conference on Wednesday, July 29, 2026, at 10:30 am ET. Management will also host one-on-one inve

About This EventAvalo Therapeutics (Nasdaq: AVTX), a clinical-stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, visits the Nasdaq MarketSite in Times Square.In honor of the occasion, Garry A. Neil, MD, Chief Executive Officer rings the Closing Bell.

WAYNE, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to...